FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149414894> ?p ?o ?g. }

• W2149414894 endingPage "3796" @default.
• W2149414894 startingPage "3794" @default.
• W2149414894 abstract "Whether local therapy in the setting of metastatic cancer can affect overall survival is a matter of debate in oncologic practice. For a cancer to metastasize, it should be microscopically present in the systemic circulation, rightfully justifying the need for systemic treatment, and perhaps questioning the utility of local therapy. Nevertheless, it has been demonstrated that the reduction of disease burden through local treatment in some disease settings does improve overall survival and can lead to long-term disease control; examples include the use of radical nephrectomy in patients with diffuse renal cell carcinoma, surgical extirpation of hepatic metastases from colorectal cancer and resection of lung metastases from a variety of primary tumor sites. In the article by Iyengar et al that accompanies this editorial, the authors highlight the importance of local therapy in previously treated metastatic non–small-cell lung cancer (NSCLC). These investigators illustrate dramatic survival outcomes using stereotactic body radiation therapy (SBRT) combined with erlotinib in 24 patients who had six or fewer sites of extracranial disease and for whom platinum-based therapy had failed. With a progression-free survival of nearly 15 months and an overall survival of 20 months (improved from traditional survival rates of 2 to 4 months and 6 to 9 months, respectively), the results seem unexpected at first glance. However, when considered in the context of oligometastatic NSCLC treated with aggressive thoracic radiotherapy, these results may not be surprising, given that other series evaluating one to two sites of extrathoracic metastases have similarly revealed prolonged median survival rates of 20 to 28 months. Likewise, there are series that have incorporated a variety of primary tumor sites (ie, breast or renal) that demonstrate remarkable survival results with SBRT for five or fewer sites of metastases. Yet the single-arm nature of these studies, none of which were randomized, confounds interpretation of these results because of potential selection bias. Selecting patients who could tolerate at least one regimen of chemotherapy and were eligible for SBRT, focal and intensified radiation therapy, to all sites of disease, implies the absence of negative prognostic factors such as pleural effusion, active brain metastases, and large tumors. Patients with large tumors ( 6 cm) would have been excluded from SBRT by virtue of the conformality and dose escalation that must be achieved; in addition, tumors of this size generally fare worse. Such criteria may indicate that the favorable selection of patients can positively affect survival measures. A similar phase II study incorporated SBRT and demonstrated a lesser median survival of 14.8 months, but patients did not uniformly receive upfront chemotherapy. Chemotherapy sensitivity may likewise select for favorable disease biology. Iyengar et al used systemic therapy that consisted of erlotinib beginning 1 week before SBRT and continuing during and after SBRT until disease progression or unacceptable toxicity. Because evaluation of epidermal growth factor receptor (EGFR) mutation status was not mandatory for this clinical trial, only 54% of patients had a mutational status determined, and none harbored an EGFR mutation. However, uncertainty exists about the impact of erlotinib on the survival of the remaining patients who did not undergo mutational status determination. Although it is unlikely that targeting the EGFR mutation influenced survival outcomes and that the main source of the survival benefit was SBRT, one cannot discern the relative benefits of SBRT and the possibility that an actionable EGFR mutation affected survival in some proportion of untested patients. The authors point out that there were no significant differences in survivals between the group that had their mutational status determined versus that which did not. This is contrary to RTOG 0324, in which cetuximab was combined with chemoradiotherapy for NSCLC, and approximately 52% of patients had a specimen analysis for EGFR testing. Komaki et al showed here that patients without EGFR immunohistochemistry (IHC) had worse overall and progression-free survival compared with those with IHC data, which suggests the importance of obtaining biopsy samples for mutational analysis. This prospective phase II trial by Iyengar et al took 6 years to reach its accrual goal. The reasons for prolonged accrual at most institutions are complex, but in this situation, it calls into the question the incidence of oligometastatic NSCLC, or more importantly, how oligometastatic disease is defined. Hellman and Weichselbaum coined the term oligometastases in Journal of Clinical Oncology in 1995 to explain a clinically significant state in which there were metastases to a single or limited number of organs, an intermediary state between locally advanced disease and widespread metastatic disease. In a series by Thibault et al, the incidence of patients able to undergo SBRT for oligometastases was 17%. Mehta et al report that 74% of patients JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 32 NUMBER 34 DECEMBER 1 2014" @default.
• W2149414894 created "2016-06-24" @default.
• W2149414894 creator A5069565044 @default.
• W2149414894 date "2014-12-01" @default.
• W2149414894 modified "2023-10-02" @default.
• W2149414894 title "Are We Expanding Oligometastatic Non–Small-Cell Lung Cancer Using Advanced Radiotherapeutic Modalities?" @default.
• W2149414894 cites W1528207664 @default.
• W2149414894 cites W1966524335 @default.
• W2149414894 cites W1969531640 @default.
• W2149414894 cites W1969931281 @default.
• W2149414894 cites W1993373616 @default.
• W2149414894 cites W2007749056 @default.
• W2149414894 cites W2035613626 @default.
• W2149414894 cites W2044315542 @default.
• W2149414894 cites W2060751282 @default.
• W2149414894 cites W2062468238 @default.
• W2149414894 cites W2065477010 @default.
• W2149414894 cites W2065799928 @default.
• W2149414894 cites W2072048806 @default.
• W2149414894 cites W2076880391 @default.
• W2149414894 cites W2080189021 @default.
• W2149414894 cites W2084470612 @default.
• W2149414894 cites W2090749716 @default.
• W2149414894 cites W2105937199 @default.
• W2149414894 cites W2108168221 @default.
• W2149414894 cites W2137602317 @default.
• W2149414894 cites W2141454678 @default.
• W2149414894 cites W2144326782 @default.
• W2149414894 cites W2397563540 @default.
• W2149414894 cites W2416385708 @default.
• W2149414894 cites W4240340450 @default.
• W2149414894 doi "https://doi.org/10.1200/jco.2014.58.5539" @default.
• W2149414894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25349298" @default.
• W2149414894 hasPublicationYear "2014" @default.
• W2149414894 type Work @default.
• W2149414894 sameAs 2149414894 @default.
• W2149414894 citedByCount "3" @default.
• W2149414894 countsByYear W21494148942015 @default.
• W2149414894 countsByYear W21494148942019 @default.
• W2149414894 crossrefType "journal-article" @default.
• W2149414894 hasAuthorship W2149414894A5069565044 @default.
• W2149414894 hasBestOaLocation W21494148941 @default.
• W2149414894 hasConcept C126322002 @default.
• W2149414894 hasConcept C126838900 @default.
• W2149414894 hasConcept C143998085 @default.
• W2149414894 hasConcept C144024400 @default.
• W2149414894 hasConcept C2776256026 @default.
• W2149414894 hasConcept C2777714996 @default.
• W2149414894 hasConcept C2779903281 @default.
• W2149414894 hasConcept C36289849 @default.
• W2149414894 hasConcept C71924100 @default.
• W2149414894 hasConceptScore W2149414894C126322002 @default.
• W2149414894 hasConceptScore W2149414894C126838900 @default.
• W2149414894 hasConceptScore W2149414894C143998085 @default.
• W2149414894 hasConceptScore W2149414894C144024400 @default.
• W2149414894 hasConceptScore W2149414894C2776256026 @default.
• W2149414894 hasConceptScore W2149414894C2777714996 @default.
• W2149414894 hasConceptScore W2149414894C2779903281 @default.
• W2149414894 hasConceptScore W2149414894C36289849 @default.
• W2149414894 hasConceptScore W2149414894C71924100 @default.
• W2149414894 hasIssue "34" @default.
• W2149414894 hasLocation W21494148941 @default.
• W2149414894 hasLocation W21494148942 @default.
• W2149414894 hasOpenAccess W2149414894 @default.
• W2149414894 hasPrimaryLocation W21494148941 @default.
• W2149414894 hasRelatedWork W1967103478 @default.
• W2149414894 hasRelatedWork W2032912323 @default.
• W2149414894 hasRelatedWork W2049214470 @default.
• W2149414894 hasRelatedWork W2213819692 @default.
• W2149414894 hasRelatedWork W2372561159 @default.
• W2149414894 hasRelatedWork W2375344515 @default.
• W2149414894 hasRelatedWork W2386285196 @default.
• W2149414894 hasRelatedWork W2390152934 @default.
• W2149414894 hasRelatedWork W2392484045 @default.
• W2149414894 hasRelatedWork W3005652238 @default.
• W2149414894 hasVolume "32" @default.
• W2149414894 isParatext "false" @default.
• W2149414894 isRetracted "false" @default.
• W2149414894 magId "2149414894" @default.
• W2149414894 workType "article" @default.